Camurus AB

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0007692850
SEK
457.00
6.2 (1.38%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

  • INTEREST COVERAGE RATIO(Q) Lowest at 7,981.78
  • NET SALES(Q) Lowest at SEK 464.46 MM
  • INTEREST(Q) Highest at SEK 1.57 MM
2

With ROE of 18.56%, it has a expensive valuation with a 10.30 Price to Book Value

3

Underperformed the market in the last 1 year

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

SEK 28,061 Million (Mid Cap)

stock-summary
P/E

55.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.87

stock-summary
Return on Equity

17.37%

stock-summary
Price to Book

6.63

Revenue and Profits:
Net Sales:
464 Million
(Quarterly Results - Dec 2025)
Net Profit:
101 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-24.65%
0%
-24.65%
6 Months
-31.74%
0%
-31.74%
1 Year
-23.39%
0%
-23.39%
2 Years
-12.79%
0%
-12.79%
3 Years
114.35%
0%
114.35%
4 Years
185.27%
0%
185.27%
5 Years
118.66%
0%
118.66%

Camurus AB for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
46.47%
EBIT Growth (5y)
44.33%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.82
Sales to Capital Employed (avg)
0.68
Tax Ratio
22.81%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
53.15%
ROE (avg)
8.72%

Valuation key factors

Factor
Value
P/E Ratio
55
Industry P/E
Price to Book Value
10.30
EV to EBIT
43.28
EV to EBITDA
42.32
EV to Capital Employed
67.36
EV to Sales
16.12
PEG Ratio
0.26
Dividend Yield
NA
ROCE (Latest)
155.65%
ROE (Latest)
18.56%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -18.09% vs -16.05% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -47.61% vs -21.32% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "464.50",
          "val2": "567.10",
          "chgp": "-18.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "125.30",
          "val2": "243.70",
          "chgp": "-48.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.60",
          "val2": "1.40",
          "chgp": "14.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "100.90",
          "val2": "192.60",
          "chgp": "-47.61%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "255.50%",
          "val2": "418.40%",
          "chgp": "-16.29%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 21.30% vs 8.78% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 71.71% vs -0.70% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,265.40",
          "val2": "1,867.60",
          "chgp": "21.30%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "909.20",
          "val2": "483.60",
          "chgp": "88.01%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "5.80",
          "val2": "1.10",
          "chgp": "427.27%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "735.60",
          "val2": "428.40",
          "chgp": "71.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "390.30%",
          "val2": "252.00%",
          "chgp": "13.83%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQstock-summary

Dec'25
Sep'25
Change(%)
Net Sales
464.50
567.10
-18.09%
Operating Profit (PBDIT) excl Other Income
125.30
243.70
-48.58%
Interest
1.60
1.40
14.29%
Exceptional Items
0.00
0.00
Consolidate Net Profit
100.90
192.60
-47.61%
Operating Profit Margin (Excl OI)
255.50%
418.40%
-16.29%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2025 is -18.09% vs -16.05% in Sep 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is -47.61% vs -21.32% in Sep 2025

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
2,265.40
1,867.60
21.30%
Operating Profit (PBDIT) excl Other Income
909.20
483.60
88.01%
Interest
5.80
1.10
427.27%
Exceptional Items
0.00
0.10
-100.00%
Consolidate Net Profit
735.60
428.40
71.71%
Operating Profit Margin (Excl OI)
390.30%
252.00%
13.83%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is 21.30% vs 8.78% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 71.71% vs -0.70% in Dec 2024

stock-summaryCompany CV
About Camurus AB stock-summary
stock-summary
Camurus AB
Pharmaceuticals & Biotechnology
Camurus AB is a Sweden-based research and development based pharmaceutical company with a focus on the development and commercialization of specialty medicines, providing patients suffering from serious and chronic disease, such as opioid dependence, pain, cancer, acromegaly, and neuroendocrine tumors. The Company has a diversified research portfolio, which includes five products in clinical trials, and a number of additional product candidates in the pre-clinical phase. The Company’s product pipeline represents a mix of in-house and partnered projects in different development phases. Camurus AB is the parent company of the Group, which comprises four legal entities, namely Camurus Inc, Cubosome Inc, Camurus Development AB and Bioimplant Scandinavia AB.
Company Coordinates stock-summary
Company Details
Solvegatan 41 , LUND None : 223 62
stock-summary
Tel: 46 46 286573046 708 537292
stock-summary
Registrar Details